Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Oct 31;9(2):e0113821.
doi: 10.1128/Spectrum.01138-21. Epub 2021 Oct 20.

COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave

Stéphane Bretagne  1   2   3 , Karine Sitbon  1 , Françoise Botterel  4 , Sarah Dellière  1   2   3 , Valérie Letscher-Bru  5 , Taieb Chouaki  6 , Anne-Pauline Bellanger  7 , Christine Bonnal  8 , Arnault Fekkar  9 , Florence Persat  10 , Damien Costa  11 , Nathalie Bourgeois  12 , Frédéric Dalle  13 , Florian Lussac-Sorton  14 , André Paugam  3   15 , Sophie Cassaing  16 , Lilia Hasseine  17 , Antoine Huguenin  18 , Nadia Guennouni  19 , Edith Mazars  20 , Solène Le Gal  21 , Milène Sasso  22 , Sophie Brun  23 , Lucile Cadot  24 , Carole Cassagne  25 , Estelle Cateau  26 , Jean-Pierre Gangneux  27 , Maxime Moniot  28 , Anne-Laure Roux  29 , Céline Tournus  30 , Nicole Desbois-Nogard  31 , Alain Le Coustumier  32 , Olivier Moquet  33 , Alexandre Alanio  1   2   3 , Françoise Dromer  1 ; French Mycoses Study Group
Affiliations
Observational Study

COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave

Stéphane Bretagne et al. Microbiol Spectr. .

Abstract

The aim of this study was to evaluate diagnostic means, host factors, delay of occurrence, and outcome of patients with COVID-19 pneumonia and fungal coinfections in the intensive care unit (ICU). From 1 February to 31 May 2020, we anonymously recorded COVID-19-associated pulmonary aspergillosis (CAPA), fungemia (CA-fungemia), and pneumocystosis (CA-PCP) from 36 centers, including results on fungal biomarkers in respiratory specimens and serum. We collected data from 154 episodes of CAPA, 81 of CA-fungemia, 17 of CA-PCP, and 5 of other mold infections from 244 patients (male/female [M/F] ratio = 3.5; mean age, 64.7 ± 10.8 years). CA-PCP occurred first after ICU admission (median, 1 day; interquartile range [IQR], 0 to 3 days), followed by CAPA (9 days; IQR, 5 to 13 days), and then CA-fungemia (16 days; IQR, 12 to 23 days) (P < 10-4). For CAPA, the presence of several mycological criteria was associated with death (P < 10-4). Serum galactomannan was rarely positive (<20%). The mortality rates were 76.7% (23/30) in patients with host factors for invasive fungal disease, 45.2% (14/31) in those with a preexisting pulmonary condition, and 36.6% (34/93) in the remaining patients (P = 0.001). Antimold treatment did not alter prognosis (P = 0.370). Candida albicans was responsible for 59.3% of CA-fungemias, with a global mortality of 45.7%. For CA-PCP, 58.8% of the episodes occurred in patients with known host factors of PCP, and the mortality rate was 29.5%. CAPA may be in part hospital acquired and could benefit from antifungal prescription at the first positive biomarker result. CA-fungemia appeared linked to ICU stay without COVID-19 specificity, while CA-PCP may not really be a concern in the ICU. Improved diagnostic strategy for fungal markers in ICU patients with COVID-19 should support these hypotheses. IMPORTANCE To diagnose fungal coinfections in patients with COVID-19 in the intensive care unit, it is necessary to implement the correct treatment and to prevent them if possible. For COVID-19-associated pulmonary aspergillosis (CAPA), respiratory specimens remain the best approach since serum biomarkers are rarely positive. Timing of occurrence suggests that CAPA could be hospital acquired. The associated mortality varies from 36.6% to 76.7% when no host factors or host factors of invasive fungal diseases are present, respectively. Fungemias occurred after 2 weeks in ICUs and are associated with a mortality rate of 45.7%. Candida albicans is the first yeast species recovered, with no specificity linked to COVID-19. Pneumocystosis was mainly found in patients with known immunodepression. The diagnosis occurred at the entry in ICUs and not afterwards, suggesting that if Pneumocystis jirovecii plays a role, it is upstream of the hospitalization in the ICU.

Keywords: Aspergillus; COVID-19; France; aspergillosis; critical care; fungemia; pneumocystosis.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Delays between admission in the ICU and diagnosis of fungal diseases of the 257 episodes of the present study with significantly difference according to fungal disease: CA-PCP occurred first (n = 17; median delay, 1 day; interquartile range [IQR], 0 to 3 days), followed by CAPA (n = 154; 9 days; IQR, 5 to 13 days) and CA-non-Aspergillus diseases (n = 5; 11 days, IQR, 7 to 33 days), and CA-fungemia (16 days; IQR, 12 to 23 days) (P < 10−4).
FIG 2
FIG 2
Overall survival after diagnosis of CAPA according to the diagnostic mycological criteria with either one (blue line), two (brown line), three (green line), or more than 4 (yellow line) criteria in the whole population studied (Kaplan-Meier analysis, log rank test, P = 0.0020).
FIG 3
FIG 3
Overall survival after diagnosis of CAPA according to the diagnostic mycological criteria with either one (blue line), two (brown line), three (green line), or more than 4 (yellow line) criteria in patients with no known host factors for invasive fungal diseases and with no history of severe respiratory disease (Kaplan-Meier analysis, log rank test, P = 0.0768).
See this image and copyright information in PMC

Similar articles

  • Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study.
    Gangneux JP, Dannaoui E, Fekkar A, Luyt CE, Botterel F, De Prost N, Tadié JM, Reizine F, Houzé S, Timsit JF, Iriart X, Riu-Poulenc B, Sendid B, Nseir S, Persat F, Wallet F, Le Pape P, Canet E, Novara A, Manai M, Cateau E, Thille AW, Brun S, Cohen Y, Alanio A, Mégarbane B, Cornet M, Terzi N, Lamhaut L, Sabourin E, Desoubeaux G, Ehrmann S, Hennequin C, Voiriot G, Nevez G, Aubron C, Letscher-Bru V, Meziani F, Blaize M, Mayaux J, Monsel A, Boquel F, Robert-Gangneux F, Le Tulzo Y, Seguin P, Guegan H, Autier B, Lesouhaitier M, Pelletier R, Belaz S, Bonnal C, Berry A, Leroy J, François N, Richard JC, Paulus S, Argaud L, Dupont D, Menotti J, Morio F, Soulié M, Schwebel C, Garnaud C, Guitard J, Le Gal S, Quinio D, Morcet J, Laviolle B, Zahar JR, Bougnoux ME. Gangneux JP, et al. Lancet Respir Med. 2022 Feb;10(2):180-190. doi: 10.1016/S2213-2600(21)00442-2. Epub 2021 Nov 26. Lancet Respir Med. 2022. PMID: 34843666 Free PMC article.
  • Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study.
    Feys S, Gonçalves SM, Khan M, Choi S, Boeckx B, Chatelain D, Cunha C, Debaveye Y, Hermans G, Hertoghs M, Humblet-Baron S, Jacobs C, Lagrou K, Marcelis L, Maizel J, Meersseman P, Nyga R, Seldeslachts L, Starick MR, Thevissen K, Vandenbriele C, Vanderbeke L, Vande Velde G, Van Regenmortel N, Vanstapel A, Vanmassenhove S, Wilmer A, Van De Veerdonk FL, De Hertogh G, Mombaerts P, Lambrechts D, Carvalho A, Van Weyenbergh J, Wauters J. Feys S, et al. Lancet Respir Med. 2022 Dec;10(12):1147-1159. doi: 10.1016/S2213-2600(22)00259-4. Epub 2022 Aug 24. Lancet Respir Med. 2022. PMID: 36029799 Free PMC article.
  • COVID-19-associated pulmonary aspergillosis (CAPA) in hematological patients: Could antifungal prophylaxis be necessary? A nationwide study.
    Tamayo-Velasco Á, López-Herrero R, Gómez-García LM, Sánchez-de Prada L, Aguilar-Monserrate G, Martín-Fernández M, Bardají-Carrillo M, Álvaro-Meca A, Tamayo E, Resino S, Miramontes-González JP, Peñarrubia-Ponce MJ. Tamayo-Velasco Á, et al. J Infect Public Health. 2024 Jun;17(6):939-946. doi: 10.1016/j.jiph.2024.04.005. Epub 2024 Apr 10. J Infect Public Health. 2024. PMID: 38613930
  • Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.
    Verweij PE, Rijnders BJA, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, Calandra T, Clancy CJ, Cornely OA, Chiller T, Depuydt P, Giacobbe DR, Janssen NAF, Kullberg BJ, Lagrou K, Lass-Flörl C, Lewis RE, Liu PW, Lortholary O, Maertens J, Martin-Loeches I, Nguyen MH, Patterson TF, Rogers TR, Schouten JA, Spriet I, Vanderbeke L, Wauters J, van de Veerdonk FL. Verweij PE, et al. Intensive Care Med. 2020 Aug;46(8):1524-1535. doi: 10.1007/s00134-020-06091-6. Epub 2020 Jun 22. Intensive Care Med. 2020. PMID: 32572532 Free PMC article.
  • Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis.
    Kariyawasam RM, Dingle TC, Kula BE, Vandermeer B, Sligl WI, Schwartz IS. Kariyawasam RM, et al. Clin Microbiol Infect. 2022 Jul;28(7):920-927. doi: 10.1016/j.cmi.2022.01.027. Epub 2022 Feb 10. Clin Microbiol Infect. 2022. PMID: 35150878 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Verweij PE, Rijnders BJA, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, Calandra T, Clancy CJ, Cornely OA, Chiller T, Depuydt P, Giacobbe DR, Janssen NAF, Kullberg B-J, Lagrou K, Lass-Florl C, Lewis RE, Liu PW-L, Lortholary O, Maertens J, Martin-Loeches I, Nguyen MH, Patterson TF, Rogers TR, Schouten JA, Spriet I, Vanderbeke L, Wauters J, van de Veerdonk FL. 2020. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med 46:1524–1535. doi:10.1007/s00134-020-06091-6. - DOI - PMC - PubMed
    1. Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, Lagrou K, Verweij PE, van de Veerdonk FL, Gommers D, Spronk P, Bergmans DCJJ, Hoedemaekers A, Andrinopoulou E-R, van den Berg CHSB, Juffermans NP, Hodiamont CJ, Vonk AG, Depuydt P, Boelens J, Wauters J, Dutch-Belgian Mycosis Study Group. 2018. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 6:782–792. doi:10.1016/S2213-2600(18)30274-1. - DOI - PubMed
    1. White PL, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S, Pandey M, Whitaker H, May A, Morgan M, Wise MP, Healy B, Blyth I, Price JS, Vale L, Posso R, Kronda J, Blackwood A, Rafferty H, Moffitt A, Tsitsopoulou A, Gaur S, Holmes T, Backx M. 2020. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis 56:e01122. - PMC - PubMed
    1. Arastehfar A, Carvalho A, Nguyen MH, Hedayati MT, Netea MG, Perlin DS, Hoenigl M. 2020. COVID-19-associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions? J Fungi (Basel) 6:211. doi:10.3390/jof6040211. - DOI - PMC - PubMed
    1. Alanio A, Bretagne S. 2017. Pneumocystis jirovecii detection in asymptomatic patients: what does its natural history tell us? F1000Res 6:739. doi:10.12688/f1000research.10619.1. - DOI - PMC - PubMed

Publication types

MeSH terms